Tissue | Expression Dynamics | Abbreviation |
Endometrium | | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | | BPH: Benign Prostatic Hyperplasia |
Skin | | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004578516 | Endometrium | AEH | positive regulation of cell adhesion | 96/2100 | 437/18723 | 5.50e-11 | 7.18e-09 | 96 |
GO:00715596 | Endometrium | AEH | response to transforming growth factor beta | 53/2100 | 256/18723 | 7.01e-06 | 1.69e-04 | 53 |
GO:00715606 | Endometrium | AEH | cellular response to transforming growth factor beta stimulus | 51/2100 | 250/18723 | 1.59e-05 | 3.32e-04 | 51 |
GO:002240714 | Endometrium | AEH | regulation of cell-cell adhesion | 79/2100 | 448/18723 | 2.90e-05 | 5.40e-04 | 79 |
GO:002240910 | Endometrium | AEH | positive regulation of cell-cell adhesion | 54/2100 | 284/18723 | 6.94e-05 | 1.07e-03 | 54 |
GO:19030398 | Endometrium | AEH | positive regulation of leukocyte cell-cell adhesion | 46/2100 | 239/18723 | 1.72e-04 | 2.24e-03 | 46 |
GO:00421109 | Endometrium | AEH | T cell activation | 81/2100 | 487/18723 | 1.78e-04 | 2.30e-03 | 81 |
GO:00509008 | Endometrium | AEH | leukocyte migration | 64/2100 | 369/18723 | 2.57e-04 | 3.04e-03 | 64 |
GO:00508709 | Endometrium | AEH | positive regulation of T cell activation | 41/2100 | 216/18723 | 5.08e-04 | 5.18e-03 | 41 |
GO:00071599 | Endometrium | AEH | leukocyte cell-cell adhesion | 63/2100 | 371/18723 | 5.11e-04 | 5.21e-03 | 63 |
GO:00508639 | Endometrium | AEH | regulation of T cell activation | 57/2100 | 329/18723 | 5.58e-04 | 5.59e-03 | 57 |
GO:00027645 | Endometrium | AEH | immune response-regulating signaling pathway | 76/2100 | 468/18723 | 5.76e-04 | 5.71e-03 | 76 |
GO:00380934 | Endometrium | AEH | Fc receptor signaling pathway | 14/2100 | 50/18723 | 8.97e-04 | 8.24e-03 | 14 |
GO:19030379 | Endometrium | AEH | regulation of leukocyte cell-cell adhesion | 57/2100 | 336/18723 | 9.42e-04 | 8.57e-03 | 57 |
GO:00026838 | Endometrium | AEH | negative regulation of immune system process | 69/2100 | 434/18723 | 1.76e-03 | 1.41e-02 | 69 |
GO:00024332 | Endometrium | AEH | immune response-regulating cell surface receptor signaling pathway involved in phagocytosis | 8/2100 | 27/18723 | 7.74e-03 | 4.33e-02 | 8 |
GO:00380962 | Endometrium | AEH | Fc-gamma receptor signaling pathway involved in phagocytosis | 8/2100 | 27/18723 | 7.74e-03 | 4.33e-02 | 8 |
GO:004578517 | Endometrium | EEC | positive regulation of cell adhesion | 98/2168 | 437/18723 | 6.15e-11 | 8.38e-09 | 98 |
GO:002240715 | Endometrium | EEC | regulation of cell-cell adhesion | 84/2168 | 448/18723 | 4.98e-06 | 1.24e-04 | 84 |
GO:007155914 | Endometrium | EEC | response to transforming growth factor beta | 54/2168 | 256/18723 | 8.25e-06 | 1.83e-04 | 54 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
YES1 | SNV | Missense_Mutation | rs763332220 | c.137N>T | p.Ser46Leu | p.S46L | P07947 | protein_coding | tolerated(0.07) | benign(0.027) | TCGA-A2-A04W-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
YES1 | SNV | Missense_Mutation | | c.760G>C | p.Val254Leu | p.V254L | P07947 | protein_coding | deleterious(0.04) | benign(0.02) | TCGA-BH-A0DG-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
YES1 | insertion | In_Frame_Ins | novel | c.116_117insAGG | p.Val39_Ser40insGly | p.V39_S40insG | P07947 | protein_coding | | | TCGA-A8-A08H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
YES1 | insertion | Nonsense_Mutation | novel | c.115_116insGCCATTCTAATAACTGTAAAGATAAACTCTAA | p.Val39GlyfsTer11 | p.V39Gfs*11 | P07947 | protein_coding | | | TCGA-A8-A08H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
YES1 | insertion | Nonsense_Mutation | novel | c.57_58insGAGAGAAAATGAGCTCTTTTGTAAAGGGTCCCGTATCAGGATGCTT | p.Asn20GlufsTer4 | p.N20Efs*4 | P07947 | protein_coding | | | TCGA-BH-A0B4-01 | Breast | breast invasive carcinoma | Male | >=65 | III/IV | Hormone Therapy | tamoxiphen | SD |
YES1 | deletion | Frame_Shift_Del | novel | c.846delN | p.Lys282AsnfsTer2 | p.K282Nfs*2 | P07947 | protein_coding | | | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD |
YES1 | SNV | Missense_Mutation | | c.388N>A | p.Glu130Lys | p.E130K | P07947 | protein_coding | tolerated(0.35) | benign(0.062) | TCGA-DG-A2KM-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
YES1 | SNV | Missense_Mutation | | c.1034N>C | p.Tyr345Ser | p.Y345S | P07947 | protein_coding | deleterious(0) | probably_damaging(0.98) | TCGA-Q1-A5R1-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
YES1 | SNV | Missense_Mutation | rs202083013 | c.403G>A | p.Ala135Thr | p.A135T | P07947 | protein_coding | tolerated(1) | benign(0) | TCGA-AA-3663-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
YES1 | SNV | Missense_Mutation | | c.1153N>A | p.Ala385Thr | p.A385T | P07947 | protein_coding | deleterious(0.02) | possibly_damaging(0.748) | TCGA-AA-3715-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
7525 | YES1 | DRUGGABLE GENOME, KINASE, TYROSINE KINASE, ENZYME, CLINICALLY ACTIONABLE | | GSK-625137A | GSK-625137A | |
7525 | YES1 | DRUGGABLE GENOME, KINASE, TYROSINE KINASE, ENZYME, CLINICALLY ACTIONABLE | | GW831090X | GW831090X | |
7525 | YES1 | DRUGGABLE GENOME, KINASE, TYROSINE KINASE, ENZYME, CLINICALLY ACTIONABLE | | SB-221466 | CHEMBL95502 | |
7525 | YES1 | DRUGGABLE GENOME, KINASE, TYROSINE KINASE, ENZYME, CLINICALLY ACTIONABLE | | GW827102X | GW827102X | |
7525 | YES1 | DRUGGABLE GENOME, KINASE, TYROSINE KINASE, ENZYME, CLINICALLY ACTIONABLE | | SB-203580 | SB-203580 | |
7525 | YES1 | DRUGGABLE GENOME, KINASE, TYROSINE KINASE, ENZYME, CLINICALLY ACTIONABLE | | GW631581B | GW631581B | |
7525 | YES1 | DRUGGABLE GENOME, KINASE, TYROSINE KINASE, ENZYME, CLINICALLY ACTIONABLE | | CYC-116 | CYC-116 | |
7525 | YES1 | DRUGGABLE GENOME, KINASE, TYROSINE KINASE, ENZYME, CLINICALLY ACTIONABLE | | GW837331X | GW837331X | |
7525 | YES1 | DRUGGABLE GENOME, KINASE, TYROSINE KINASE, ENZYME, CLINICALLY ACTIONABLE | | SK&F-86002 | CHEMBL313417 | |
7525 | YES1 | DRUGGABLE GENOME, KINASE, TYROSINE KINASE, ENZYME, CLINICALLY ACTIONABLE | | REGORAFENIB | REGORAFENIB | |